Field Guide · Deconstructed
SOT — Supportive Oligonucleotide Technique — is a lab-made strand of genetic material designed to match a specific bug’s code and quietly shut down its replication, given as a slow-acting injection that works over months. The idea borrows from real, FDA-approved gene-silencing science. The specific product — made by one company in Greece — has almost no independent evidence behind it. Here are the honest facts: what it is, what the research actually shows (and doesn’t), the “works ~30% of the time” number you may hear and why it doesn’t hold up, the real cost and logistics, and where it sits on the kill-menu.
I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.
This is aimed at chronic, persister-driven tick-borne infection — Borrelia (Lyme), and (per the clinics) Bartonella, Babesia, and some viruses like EBV — the kind that hasn’t cleared after antibiotics and herbs. It’s positioned as one option on the refractory end of the Lyme full kill-menu, for a case that’s genuinely stuck. The honest caveat up front: this is an experimental, unproven entry on that menu — not an evidence-supported one. Read the research section before you spend a dollar.
SOT stands for Supportive Oligonucleotide Technique. The concept: take a sample of your child’s blood, identify the genetic sequence of the pathogen in it, then synthesize a short, custom strand of genetic material (an oligonucleotide) designed to bind that bug’s sequence and block it from replicating. It’s given as a slow-release IV infusion that’s said to stay “at work” in the body for up to six months, so it’s dosed only a few times a year rather than daily.
It is made by a single company — RGCC (Research Genetic Cancer Centre), a liquid-biopsy lab founded in 2004 by Dr. Ioannis Papasotiriou, with its lab in Florina, Greece (US testing arm in Denver; holding company in Switzerland). The molecule itself is synthesized in Greece and shipped back for infusion. RGCC — about · RGCC founder
Gene-silencing oligonucleotides are legitimate, FDA-approved medicine — for other drugs. Antisense and RNA-interference therapies treat real diseases (spinal muscular atrophy, a form of inherited blindness, an IgA kidney disease) and won a Nobel Prize for the underlying biology. So the category is not fringe.
But two honest distinctions matter. One: “the mechanism class is real” is not the same as “this specific product works” — the approved drugs went through years of controlled trials that SOT has not. Two: the marketing usually calls SOT an “antisense oligonucleotide,” but RGCC’s own published paper describes it as small interfering RNA (siRNA) — a related but distinct gene-silencing approach. A small detail, but it’s the kind of imprecision that tells you to read the claims closely. Apostolou et al., Infectious Disease Reports 2022
This is the part that matters most, and it’s blunt: for SOT in Lyme and tick-borne disease, the entire peer-reviewed human evidence base is a single paper — uncontrolled, written by the company that sells it, and measuring pathogen DNA rather than whether anyone actually got better.
The lone publication is a 2022 paper in Infectious Disease Reports. Here is what it is, honestly:
Reducing detectable DNA is not the same as a child getting well — that gap is the whole problem with the evidence here. Apostolou et al., Infectious Disease Reports 2022 (PMID 36412742)
The honest label: a real mechanism class wrapped around a product with almost no independent evidence. Compare it to the rest of the kill-menu — the herbs at least have in-vitro lab data; dapsone and disulfiram have published human case series. SOT has one uncontrolled, vendor-authored, DNA-marker study. That doesn’t make it a scam by itself, but it puts it firmly in the experimental / unproven tier — a “maybe, eyes wide open, and not first” option, not a “this works.”
You may hear a Lyme-literate practitioner say SOT “works about 30% of the time.” It’s worth knowing exactly where that figure comes from, because it has no study behind it as an efficacy number.
Tracing it back, the only place “30%” appears in the SOT literature is on a skeptical physician’s page — and there it means two things, neither one an efficacy rate:
So “works ~30% of the time” appears to be folklore — a game-of-telephone inversion of a placebo-baseline and a PCR-sensitivity stat into a made-up success rate. Treat it as anecdotal, not an established statistic. Marty Ross MD — “Is SOT for Lyme a Scam?” (archived)
Tellingly, the numbers the clinics quote aren’t 30% at all — they’re very high: figures like “95% of Lyme patients show a positive clinical response” and “91% of chronic-viral patients improve.” But those come straight from RGCC’s own unpublished internal reports — the manufacturer’s marketing, not the peer-reviewed paper (which, remember, never measured symptoms at all). So you’re left with a low folklore number with no source and a high marketing number with an obvious conflict of interest — and no neutral, controlled figure anywhere in between. The honest read: nobody actually knows how often SOT helps. LymeDisease.org — SOT overview · Daniel Cameron MD
If a family is weighing SOT anyway, here’s the honest logistics — what it costs, how it’s ordered, how slow it is, and the one part that’s genuinely a point in its favor.
| What | The honest detail |
|---|---|
| How it’s ordered | Through a Lyme-literate / integrative practitioner (mostly naturopathic) who works with RGCC. Two blood draws go to Greece — one to identify and quantify the bug, a second to make the custom molecule (~4 weeks) — then it’s shipped back for IV infusion. |
| Cost | Roughly $1,500–$5,000 per single-pathogen dose (a commonly cited figure is ~$2,750), plus the RGCC testing (often $1,250–$3,100). One dose = one bug, so co-infections multiply the cost. All-in often $5,000–$10,000+/year, and insurance rarely covers any of it. |
| Timeline | Slow by design. Each dose is said to keep working for up to ~6 months; benefits, if any, show up gradually over weeks to months, not days. RGCC caps it at 9 doses/year total and 4/year for the same target (spaced ≥3 months) — an effective Lyme cadence of roughly every 3–4 months, retesting the bug between doses. |
| Herx | Because it kills slowly rather than all at once, practitioners report the die-off (Herx) tends to be milder and better-tolerated — a plausible, honestly appealing point. Be clear-eyed, though: this is a practitioner/marketing framing, not a proven finding — RGCC’s own guide only says Herx “can occur,” and clinics still describe reactions lasting days to a few weeks. |
Sources: clinic cost/logistics · Project Lyme — SOT overview · LymeDisease.org — SOT part two (slow action / Herx) · RGCC SOT Patient Guide (dosing caps, 6-month lifespan).
SOT is not a standalone cure — and is never sold as a one-and-done. It’s layered into the rest of the kill-menu, dosed repeatedly across a year, each round its own four-figure cost. So the honest cost question isn’t “can we afford one infusion” — it’s “can we afford a year of them, for an unproven product, when that same money could fund testing and treatments with real evidence behind them.”
This tree is only for a refractory case — a child genuinely stuck after the evidence-backed options — where SOT is even worth a conversation. Start at the top and follow your situation. Tap to open.
SOT is an experimental, unproven entry. Before it belongs on the table, the things with actual evidence should have had a fair run: targeted antibiotics, the Buhner/Cowden herbs, biofilm work, and the right sequencing (see the full kill-menu). If those haven’t been tried, start there — they cost less and have more behind them. If the case is genuinely refractory → keep going ↓
Make sure everyone — you and the practitioner — can say out loud what’s true: one uncontrolled, vendor-authored, DNA-marker study; no RCTs; nothing published for Bartonella or Babesia; not FDA-approved; the “30%” figure is folklore. A practitioner who can’t say all that plainly is the wrong practitioner.
A year of SOT can run $5,000–$10,000+ out of pocket. Ask honestly: could that money buy more evidence-backed testing or treatment first? If SOT still makes sense for your situation, treat it as one layer in the plan, not the plan. Jump to access.
Because the slow action makes “I think it’s helping” easy to believe, decide the read-out in advance: which symptoms, on what timeline, and what would tell you it’s NOT working — so you don’t fund dose after dose on hope. Anchor it to your child’s daily tracking, not a feeling.
This is exactly the kind of expensive, hard-to-judge call you shouldn’t weigh alone. Minta has the evidence on SOT synthesized — she’ll tell you honestly whether it even belongs on your child’s table (often the answer is “not yet, try the proven options first”), what it would cost against the alternatives, and how to define “is this working” before you spend. Let Minta think it through with you →
LymeDisease.org · clinic process overview · Knoepfler — regulatory status
Credentials, polish, and how conventional an approach sounds tell you little about whether a practitioner will help your child — or harm them. What does: their behavior and their incentives. Watch those.
A custom genetic injection made in Greece sounds futuristic — so the strangeness tells you nothing either way. What tells you everything is whether the practitioner is honest about how thin the evidence is, and whether they profit more the more doses you buy. Judge the conduct and the incentives.
SOT is a real idea built on legitimate gene-silencing science — a custom-made strand designed to quietly shut down a specific bug, dosed slowly a few times a year, with a die-off that may be gentler because it kills slowly. But the specific product’s evidence is among the thinnest on this whole map: one uncontrolled, manufacturer-authored study that measured pathogen DNA rather than whether anyone got better, in only 28 Lyme patients; no randomized trials, nothing published for Bartonella or Babesia, and no FDA approval. The “works ~30% of the time” figure you may hear is folklore with no study behind it, and the high numbers clinics quote are the vendor’s own marketing. So SOT sits in the experimental, unproven tier of the Lyme kill-menu — a possible late layer for a genuinely refractory case, for a family with eyes wide open and money to spend, after the proven options have had a fair trial — not a cure, a first move, or a standalone. This is parent education, not medical advice — bring it to your team as questions, not instructions.
Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.